Definium Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

DFTX$34.64-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)	March 31, 2026(unaudited)	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$262,518	$257,837
Short-term investments	110,904	153,756
Prepaid and other current assets	7,141	7,727
Total current assets	380,563	419,320
Goodwill	19,918	19,918
Other non-current assets	812	862
Total assets	$401,293	$440,100
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$7,127	$5,347
Accrued expenses	24,514	20,446
2022 USD Financing Warrants	49,471	40,905
Total current liabilities	81,112	66,698
Credit facility, long-term	40,773	40,579
Other non-current liabilities	559	496
Total liabilities	122,444	107,773
Commitments and contingencies (Note 10)
Shareholders' equity:
Common shares, no par value, unlimited authorized as of March 31, 2026 and December 31, 2025; 104,044,508 and 98,776,265 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	937,795	913,914
Accumulated other comprehensive income	824	1,085
Accumulated deficit	(659,770)	(582,672)
Total shareholders' equity	278,849	332,327
Total liabilities and shareholders' equity	$401,293	$440,100

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.